Literature DB >> 26001539

Capsule Commentary on Duru et al., Adherence to Metformin, Statins, and ACE/ARBs Within the Diabetes Health Plan (DHP).

R Brett McQueen1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26001539      PMCID: PMC4617936          DOI: 10.1007/s11606-015-3296-4

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  5 in total

Review 1.  Value-based insurance design: quality improvement but no cost savings.

Authors:  Joy L Lee; Matthew Maciejewski; Shveta Raju; William H Shrank; Niteesh K Choudhry
Journal:  Health Aff (Millwood)       Date:  2013-07       Impact factor: 6.301

2.  Evaluation of increased adherence and cost savings of an employer value-based benefits program targeting generic antihyperlipidemic and antidiabetic medications.

Authors:  Bobby Clark; Janeen DuChane; John Hou; Elan Rubinstein; Jennifer McMurray; Ian Duncan
Journal:  J Manag Care Pharm       Date:  2014-02

3.  Prescription copay reduction program for diabetic employees: impact on medication compliance and healthcare costs and utilization.

Authors:  Kavita V Nair; Kerri Miller; Joseph Saseen; Pamela Wolfe; Richard Read Allen; Jinhee Park
Journal:  Am Health Drug Benefits       Date:  2009-01

4.  Adherence to Metformin, Statins, and ACE/ARBs Within the Diabetes Health Plan (DHP).

Authors:  O Kenrik Duru; Norman Turk; Susan L Ettner; Romain Neugebauer; Tannaz Moin; Jinnan Li; Lindsay Kimbro; Charles Chan; Robert H Luchs; Abigail M Keckhafer; Anya Kirvan; Sam Ho; Carol M Mangione
Journal:  J Gen Intern Med       Date:  2015-05-06       Impact factor: 5.128

Review 5.  Association between drug insurance cost sharing strategies and outcomes in patients with chronic diseases: a systematic review.

Authors:  Bikaramjit S Mann; Lianne Barnieh; Karen Tang; David J T Campbell; Fiona Clement; Brenda Hemmelgarn; Marcello Tonelli; Diane Lorenzetti; Braden J Manns
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.